AllianceBernstein’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$263M Buy
4,872,680
+2,217,159
+83% +$129M 0.09% 178
2025
Q4
$143M Sell
2,655,521
-24,746
-0.9% -$1.19M 0.05% 291
2025
Q3
$121M Sell
2,680,267
-332,366
-11% -$15.5M 0.04% 337
2025
Q2
$139M Sell
3,012,633
-295,921
-9% -$14.5M 0.05% 281
2025
Q1
$202M Sell
3,308,554
-215,852
-6% -$12.6M 0.07% 207
2024
Q4
$199M Sell
3,524,406
-381,744
-10% -$21.3M 0.07% 220
2024
Q3
$202M Buy
3,906,150
+160,895
+4% +$7.55M 0.07% 216
2024
Q2
$156M Sell
3,745,255
-597,124
-14% -$26.7M 0.05% 258
2024
Q1
$235M Buy
4,342,379
+339,501
+8% +$17.3M 0.08% 192
2023
Q4
$205M Sell
4,002,878
-571,400
-12% -$30M 0.08% 200
2023
Q3
$265M Sell
4,574,278
-143,623
-3% -$8.8M 0.11% 162
2023
Q2
$302M Buy
4,717,901
+389,729
+9% +$26.1M 0.12% 155
2023
Q1
$300M Buy
4,328,172
+1,323,195
+44% +$93.3M 0.13% 150
2022
Q4
$216M Buy
3,004,977
+291,333
+11% +$22M 0.1% 195
2022
Q3
$193M Buy
2,713,644
+46,516
+2% +$3.37M 0.09% 192
2022
Q2
$205M Sell
2,667,128
-13,286
-0.5% -$1.01M 0.09% 194
2022
Q1
$196M Sell
2,680,414
-100,505
-4% -$6.75M 0.08% 242
2021
Q4
$173M Sell
2,780,919
-69,252
-2% -$4.06M 0.06% 287
2021
Q3
$169M Sell
2,850,171
-371,975
-12% -$24.5M 0.07% 271
2021
Q2
$215M Sell
3,222,146
-1,611,524
-33% -$105M 0.09% 223
2021
Q1
$305M Buy
4,833,670
+700,700
+17% +$43.6M 0.13% 143
2020
Q4
$256M Sell
4,132,970
-742,362
-15% -$45.6M 0.12% 151
2020
Q3
$294M Sell
4,875,332
-734,402
-13% -$44.2M 0.16% 112
2020
Q2
$330M Buy
5,609,734
+34,795
+0.6% +$2.08M 0.19% 97
2020
Q1
$311M Sell
5,574,939
-116,884
-2% -$7.14M 0.22% 92
2019
Q4
$365M Buy
5,691,823
+1,052,064
+23% +$60.3M 0.21% 101
2019
Q3
$235M Sell
4,639,759
-165,740
-3% -$7.79M 0.15% 134
2019
Q2
$218M Buy
4,805,499
+316,326
+7% +$14.7M 0.14% 144
2019
Q1
$214M Buy
4,489,173
+694,362
+18% +$34.6M 0.14% 144
2018
Q4
$197M Sell
3,794,811
-91,784
-2% -$4.93M 0.15% 139
2018
Q3
$241M Buy
3,886,595
+56,474
+1% +$3.35M 0.16% 134
2018
Q2
$212M Sell
3,830,121
-626,155
-14% -$33.8M 0.15% 145
2018
Q1
$282M Buy
4,456,276
+1,593,034
+56% +$102M 0.2% 107
2017
Q4
$175M Sell
2,863,242
-241
-0% -$15.1K 0.13% 168
2017
Q3
$183M Buy
2,863,483
+170,660
+6% +$9.96M 0.14% 147
2017
Q2
$150M Sell
2,692,823
-39,449
-1% -$2.15M 0.12% 175
2017
Q1
$149M Sell
2,732,272
-440,401
-14% -$24.2M 0.12% 170
2016
Q4
$185M Sell
3,172,673
-10,104
-0.3% -$552K 0.15% 136
2016
Q3
$172M Sell
3,182,777
-37,459
-1% -$2.41M 0.14% 145
2016
Q2
$237M Buy
3,220,236
+64,863
+2% +$4.58M 0.2% 119
2016
Q1
$202M Sell
3,155,373
-5,867
-0.2% -$370K 0.17% 134
2015
Q4
$217M Sell
3,161,240
-48,074
-1% -$3.18M 0.19% 126
2015
Q3
$190M Sell
3,209,314
-192,062
-6% -$12.2M 0.16% 142
2015
Q2
$226M Sell
3,401,376
-1,408,538
-29% -$92.8M 0.19% 121
2015
Q1
$310M Sell
4,809,914
-93,933
-2% -$5.88M 0.25% 93
2014
Q4
$289M Sell
4,903,847
-151,628
-3% -$8.55M 0.24% 98
2014
Q3
$259M Sell
5,055,475
-30,488
-0.6% -$1.52M 0.22% 109
2014
Q2
$247M Sell
5,085,963
-310,965
-6% -$15.3M 0.21% 114
2014
Q1
$280M Buy
5,396,928
+794,519
+17% +$42.3M 0.24% 102
2013
Q4
$245M Sell
4,602,409
-801,253
-15% -$40.8M 0.22% 108
2013
Q3
$250M Sell
5,403,662
-513,801
-9% -$22.6M 0.25% 94
2013
Q2
$264M Buy
+5,917,463
New +$257M 0.28% 86

Other funds holding BMY

AllianceBernstein's BMY Position: Q1 2026 in Review

AllianceBernstein increased its Bristol-Myers Squibb (BMY) stake by 83% in Q1 2026, buying an estimated $129M and bringing the position to 4,872,680 shares worth $263M. The position accounts for 0.09% of the portfolio, ranked #178.

AllianceBernstein first reported a position in BMY in Q2 2013 and has held it in 52 quarters since. The position peaked at $365M in Q4 2019. 2,519 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

  • AllianceBernstein held 4,872,680 shares of Bristol-Myers Squibb worth $263M as of Q1 2026.
  • AllianceBernstein bought 2,217,159 Bristol-Myers Squibb shares in Q1 2026, an estimated $129M.
  • Bristol-Myers Squibb made up 0.09% of AllianceBernstein's portfolio in Q1 2026, its #178 holding.
  • AllianceBernstein first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 52 quarters since.
  • AllianceBernstein's Bristol-Myers Squibb position peaked at $365M in Q4 2019.
  • 2,519 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on AllianceBernstein's 13F filing for Q1 2026, filed 15 May 2026.